Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer

{ "short_title": "Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer", "data_mode": "900", "data_mode_number": "000002473", "official_title": "A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "not_applicable", "ctgov_number": "NCT06691984", "eudract_number": null, "general_contact_email": "UroStudienKoordination@ukdd.de", "general_contact_phone": "+49 351-4582157", "hauptpruefer_dd_name": "Prof. Dr. med. Christian Thomas", "description_laie_de": "Das Hauptziel der Studie ist der Vergleich des Gesamt\u00fcberlebens der Teilnehmerinnen, die mit Xaluritamig behandelt werden, mit der vom Pr\u00fcfarzt gew\u00e4hlten Methode (Cabazitaxel oder zweite Androgenrezeptor-gerichtete Therapie [ARDT]).", "description_laie_en": "The main objective of the study is to compare overall survival in participants receivingxaluritamig versus investigator's choice (cabazitaxel or second androgenreceptor-directed therapy [ARDT]).", "description_expert_de": "Das Hauptziel der Studie ist der Vergleich des Gesamt\u00fcberlebens der Teilnehmerinnen, die mit Xaluritamig behandelt werden, mit der vom Pr\u00fcfarzt gew\u00e4hlten Methode (Cabazitaxel oder zweite Androgenrezeptor-gerichtete Therapie [ARDT]).", "description_expert_en": "The main objective of the study is to compare overall survival in participants receivingxaluritamig versus investigator's choice (cabazitaxel or second androgenreceptor-directed therapy [ARDT]).", "rechtsgrundlage_value": "AMG", "phase_amg_value": "III", "main_cat_id": 11, "sub_cat_id": 54 }